Grant: Engage Grants Program
University of Saskatchewan
$25,000.00
Evaluating Efficacy of ARC-005 Lipopeptide as Vaccine Adjuvant in Mice
EF 2016-17
Résumé
Vaccination is the most cost-effective means to protect livestock against disease and hence there is greatdemand for new, safe, stable and affordable veterinary vaccines. Adjuvants are the most important componentsof vaccines as they promote or direct immune responses through distinct mechanisms and augmentantigen-specific immune responses. Currently there is very limited number of adjuvants available for clinicaluse and there is great need for novel adjuvants that are capable of stimulating innate immune responses as wellas robust antigen specific adaptive responses. ARCI has synthesized novel synthetic ligands for variousimmune receptors such as Toll-like receptors and NOD receptors and evaluated their ability to induce immuneresponses in cell based assays. With promising results on hand, in vivo studies are now needed to confirm theirefficacy. The current proposal intends to to evaluate the lead compound ARC-005 as a vaccine antigen usingboth a soluble and nanoparticle formulation. We will include a fluorescently-labeled experimental antigen toallow us to track vaccine migration and release kinetics. A second antigen will be included to confirmimmunogenicity and we will evaluate both humoral and cell-mediated immune responses over time. Thisproject will help establishing long-term collaboration with Dr. Heather Wilson whose expertise is critical forARCI product development. The success of this project will provide a strong intellectual property to ARCI inthe field of veterinary vaccines and then later development into human vaccines. Safe and versatile adjuvantswill results in healthy livestock which will contribute to social and economic benefits to Canadians.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Saskatchewan, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
500335-2016
Name nom
Wilson, Heather
Department département
VIDO-Vaccine and Infectious Disease Organization
Organization id
16
Institution établissement
University of Saskatchewan
Province en
Saskatchewan
Province fr
Saskatchewan
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1555
Committee name en
Prairie Internal Decision Committee
Committee name fr
Comité de décision interne pour les Prairies
Area of application code
102
Area of application group en
Agriculture and primary food production
Area of application group fr
Agriculture et produits alimentaires primaires
Area of application en
Animal management (animal diseases, breeding)
Area of application fr
Gestion des animaux (maladies animales, reproduction)
Research subject code
5204
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Immunology
Research subject fr
Immunologie
Partie
1
Nb partie
1
Application title
Evaluating Efficacy of ARC-005 Lipopeptide as Vaccine Adjuvant in Mice
Keyword
NSERC
Application summary
Vaccination is the most cost-effective means to protect livestock against disease and hence there is greatdemand for new, safe, stable and affordable veterinary vaccines. Adjuvants are the most important componentsof vaccines as they promote or direct immune responses through distinct mechanisms and augmentantigen-specific immune responses. Currently there is very limited number of adjuvants available for clinicaluse and there is great need for novel adjuvants that are capable of stimulating innate immune responses as wellas robust antigen specific adaptive responses. ARCI has synthesized novel synthetic ligands for variousimmune receptors such as Toll-like receptors and NOD receptors and evaluated their ability to induce immuneresponses in cell based assays. With promising results on hand, in vivo studies are now needed to confirm theirefficacy. The current proposal intends to to evaluate the lead compound ARC-005 as a vaccine antigen usingboth a soluble and nanoparticle formulation. We will include a fluorescently-labeled experimental antigen toallow us to track vaccine migration and release kinetics. A second antigen will be included to confirmimmunogenicity and we will evaluate both humoral and cell-mediated immune responses over time. Thisproject will help establishing long-term collaboration with Dr. Heather Wilson whose expertise is critical forARCI product development. The success of this project will provide a strong intellectual property to ARCI inthe field of veterinary vaccines and then later development into human vaccines. Safe and versatile adjuvantswill results in healthy livestock which will contribute to social and economic benefits to Canadians.